Drug Type Fusion protein |
Synonyms + [1] |
Target |
Mechanism TGFBR2 inhibitors(Transforming growth factor beta receptor 2 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | CN | 17 Nov 2021 | |
Advanced cancer | Phase 1 | CN | 20 Sep 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 20 Sep 2018 |
NCT04802980 (ASCO2023) Manual | Phase 1 | 68 | chemotherapy+HB002.1T | (vwpkuwjvli) = iwglxrclov ycdjhtyqyz (cipdyauoml ) View more | Positive | 26 May 2023 | |
chemotherapy+HB002.1T (ovarian cancer) | (qzcvpxvxqj) = ohyiophqpc hirmfefzdw (hyeziyhbtx ) View more |